Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
81actual
Sites
35
Countries
Belgium, Italy, Poland +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor Decision\_Not Safety Related
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-24 | actual | When the study began enrolling |
| Primary completion | 2025-05-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-30 | actual | The whole study's end, after follow-up |
| First posted | 2023-03-27 | actual | When this record first appeared on the registry |
| Results posted | 2026-06-15 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ulcerative Colitis
Interventions
- Drug: NX-13 250mg
- Drug: NX-13 750mg
- Drug: NX-13 Placebo
Primary outcome
what the primary-completion date above is the date OFChange From Baseline in Modified Mayo Score (MMS) at Week 12
measured Baseline, Week 12
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2023-07-16 · 1.4 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-02-24 · 3.5 MB · SAP_001.pdf
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed